Cullinan Oncology Inc

NASDAQ:CGEM  
11.36
+0.56 (+5.18%)
Earnings Announcements

Cullinan Oncology Provides Corporate Update And Reports Q4

Published: 03/17/2022 11:30 GMT
Cullinan Oncology Inc (CGEM) - Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results.
Cullinan Oncology Inc - Cash, Cash Equivalents and Investments Were $430.9 Million As of December 31, 2021.
Cullinan Oncology Inc - Expect That This Balance Will Be Sufficient to Fund Operations Through 2024.
Cullinan Oncology Inc - Qtrly Loss per Share $0.74.
Revenue is expected to be $275 Million
Adjusted EPS is expected to be $5.42

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.69

More details on our Analysts Page.